Egg yolk proteins suppress azoxymethane-induced aberrant crypt foci formation and cell proliferation in the colon of rats.
Dietary proteins can influence colonic carcinogenesis; some proteins have a promotional effect, whereas others exhibit a preventive effect. Dietary egg yolk proteins have been reported to suppress the expression of colon tumors in rats. In this study, we investigated the effect of consumption egg yolk proteins on cell proliferation in a rat model of azoxymethane (AOM)-induced colon cancer. We hypothesize, based on the literature of egg yolk protein actions, that they protect against colon tumor development. Therefore, male F344 rats were fed a purified AIN-93G diet containing either 20% casein (control) or 20% egg yolk proteins for 5 weeks. After 1 week on the experimental diet, the rats were administered weekly subcutaneous injections of saline or AOM for 2 weeks to induce aberrant crypt foci. Rats were administered an intraperitoneal injection of 5-bromo-2'-deoxyuridine 1 hour before being euthanized for examination of DNA synthesis in the colonic mucosa. The contents of the cecum were analyzed for the presence of short-chain fatty acids (SCFAs). In the AOM-injected rats, the yolk protein diet suppressed aberrant crypt foci formation and reduced the proliferative 5-bromo-2'-deoxyuridine-labeling index in the proximal colon when compared with the control diet. A significant increase in cecal SCFAs was observed in the rats that were fed egg yolk proteins. These results indicate that dietary egg yolk proteins have a preventive effect on AOM-induced large bowel carcinogenesis in rats; it exerts this effect by altering cell proliferation through SCFA production. This study suggests that the consumption of egg yolk proteins might be protective against colon carcinogenesis.
Ishikawa
Shin-Ichi
S
School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan. ishikawa@vmas.kitasato-u.ac.jp
Asano
Takayuki
T
Takenoshita
Shingo
S
Nozawa
Yuuya
Y
Arihara
Keizo
K
Itoh
Makoto
M
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001397:Azoxymethane / Q000009:adverse effects; D001973:Bromodeoxyuridine / Q000378:metabolism; D002273:Carcinogens; D002364:Caseins / Q000494:pharmacology; D002432:Cecum / Q000187:drug effects / Q000503:physiopathology; D049109:Cell Proliferation / Q000187:drug effects*; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D003110:Colonic Neoplasms / Q000517:prevention & control*; D004247:DNA / Q000096:biosynthesis; D004527:Egg Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D005232:Fatty Acids, Volatile / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D011230:Precancerous Conditions / Q000178:diet therapy*; D051381:Rats; D011916:Rats, Inbred F344
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D002364:Caseins; D004527:Egg Proteins; D005232:Fatty Acids, Volatile; D004247:DNA; D001973:Bromodeoxyuridine; D001397:Azoxymethane